Glenmark Pharmaceuticals received US Food and Drug Administration approval for generic progesterone vaginal inserts, equivalent to Endometrin, boosting its women’s healthcare portfolio and expanding presence in the US fertility treatment market
The company's product is a novel fixed-dose combination nasal spray of an antihistamine and a steroid, indicated for treatment of symptoms associated with seasonal allergic rhinitis (SAR) in patients over 12 years of age.